Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

Provided By PR Newswire

Last update: Aug 5, 2024

Continued Roche CAR-T partnership progress with agreement for Poseida to initiate Phase 1b portion of P-BCMA-ALLO1 clinical trial

Strong Astellas research collaboration momentum with nomination of first allogeneic solid tumor CAR-T program target